Mark Schoenberg sold $145k of URGN
Chief Medical Officer at UroGen Pharma Ltd.. 7,373 shares at an average of $19.69, traded Feb 3, 2026, filed Feb 4, 2026.
Score components
- +15RoleOfficer
- +11Trade size$145k at market
- 0Share of holdings soldSold 4.8% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.2%, 3m +26.8%, 6m +124.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-003040, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 3, 2026 | SOpen-market sale Ordinary Shares | -1,844 | $19.69 | $36k | 150,514 | Feb 4, 2026 |
| Feb 3, 2026 | SOpen-market sale Ordinary Shares | -1,843 | $19.69 | $36k | 148,671 | Feb 4, 2026 |
| Feb 3, 2026 | SOpen-market sale Ordinary Shares | -3,686 | $19.69 | $73k | 144,985 | Feb 4, 2026 |
Related signals
Other insiders at UroGen Pharma Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | URGNsell UroGen Pharma Ltd. | Chris Degnan Chief Financial Officer | $81k 2,202 shares | -33% | |
| 14Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $37k 871 shares | -1% | |
| 16Weak | UroGen Pharma Ltd. | Jason Drew Smith General Counsel | $65k 1,519 shares | -3% | |
| 10Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $350k 10,000 shares | -7% | |
| 11Weak | URGNsell UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $143k 5,222 shares | -4% | |
| 9Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $300k 10,000 shares | -7% | |
| 24Weak | UroGen Pharma Ltd. | Jason Drew Smith General Counsel | $147k 7,479 shares | -13% | |
| 8Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $250k 10,000 shares | -7% | |
| 23Weak | URGNsell UroGen Pharma Ltd. | Chris Degnan Chief Financial Officer | $37k 2,203 shares | -49% | |
| 8Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $17k 871 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.